Literature DB >> 22191633

Pharmacological review of Caralluma R.Br. with special reference to appetite suppression and anti-obesity.

Harish Chander Dutt1, Surjeet Singh, Bharathi Avula, Ikhlas A Khan, Yashbir S Bedi.   

Abstract

Caralluma fimbriata extract has received Generally Recognized As Safe (GRAS) status for use as a nutraceutical to combat the most serious public health concern (i.e., obesity). More than 260 species grouped under the genus Caralluma (Family Apocynaceae) are distributed in tropical Asia and Mediterranean regions of the globe. Ethnobotanically, some species have been used as traditional and modern dietary ingredients to suppress appetite. Many species of Caralluma are commonly used as traditional medicine for the treatment of rheumatism, diabetes, leprosy, paralysis, and inflammation and have antimalarial, antitrypanosomal, anti-ulcer, antioxidant, antinociceptive, and antiproliferative activities. The genus is known for compounds like pregnane glycosides, flavonoid glycoside, flavones, magastigmane glycosides, pregnane steroids, steroidal glycosides, saturated and unsaturated hydrocarbons, aromatic and nonaromatic volatile compounds, and β-sitosterol. An extract of C. fimbriata (Slimaluna(®), Gencor Nutrients, Anaheim, CA, USA) is used as an anti-obesity agent and appetite suppressor. It is also seen that the pregnane glycosides isolated and identified from African Hoodia are reported as anti-obesity and appetite-suppressant compounds. On reviewing the studies undertaken on the chemistry, pharmacology, and therapeutic potential of Caralluma, it is concluded that the genus is also composed of pregnane glycosides as one of the major constituents. Availability of pregnane glycosides in Caralluma is an indication of the appetite-suppressant property of this genus. This coupled with the GRAS status of the extract of C. fimbriata has opened the possibility of developing an anti-obesity/appetite-suppressant product from other species of Caralluma. The main objective of this article is to review the studies undertaken on the plant in light of further research for anti-obesity drugs and nutraceuticals from species of Caralluma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22191633     DOI: 10.1089/jmf.2010.1555

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  8 in total

Review 1.  A review on botanical species and chemical compounds with appetite suppressing properties for body weight control.

Authors:  Katie J Astell; Michael L Mathai; Xiao Q Su
Journal:  Plant Foods Hum Nutr       Date:  2013-09       Impact factor: 3.921

2.  Evaluation of aeroponics for clonal propagation of Caralluma edulis, Leptadenia reticulata and Tylophora indica - three threatened medicinal Asclepiads.

Authors:  Pooja Mehandru; N S Shekhawat; Manoj K Rai; Vinod Kataria; H S Gehlot
Journal:  Physiol Mol Biol Plants       Date:  2014-06-22

Review 3.  Delving the Role of Caralluma fimbriata: An Edible Wild Plant to Mitigate the Biomarkers of Metabolic Syndrome.

Authors:  Rimsha Anwar; Roshina Rabail; Allah Rakha; Marcin Bryla; Marek Roszko; Rana Muhammad Aadil; Marek Kieliszek
Journal:  Oxid Med Cell Longev       Date:  2022-06-20       Impact factor: 7.310

4.  In silico evaluation of apoptogenic potential and toxicological profile of triterpenoids.

Authors:  Tanvi Himanshu Desai; Shrikant Vijayrao Joshi
Journal:  Indian J Pharmacol       Date:  2019 May-Jun       Impact factor: 1.200

5.  The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials.

Authors:  Ranil Jayawardena; Tormalli V Francis; Sachith Abhayaratna; Priyanga Ranasinghe
Journal:  BMC Complement Med Ther       Date:  2021-11-10

6.  Inhibition of α-Glucosidase, Intestinal Glucose Absorption, and Antidiabetic Properties by Caralluma europaea.

Authors:  Hayat Ouassou; Touda Zahidi; Saliha Bouknana; Mohamed Bouhrim; Hassane Mekhfi; Abderrahim Ziyyat; Abdekhaleq Legssyer; Mohamed Aziz; Mohamed Bnouham
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-29       Impact factor: 2.629

Review 7.  Current Evidence to Propose Different Food Supplements for Weight Loss: A Comprehensive Review.

Authors:  Mikiko Watanabe; Renata Risi; Davide Masi; Alessandra Caputi; Angela Balena; Giovanni Rossini; Dario Tuccinardi; Stefania Mariani; Sabrina Basciani; Silvia Manfrini; Lucio Gnessi; Carla Lubrano
Journal:  Nutrients       Date:  2020-09-20       Impact factor: 5.717

8.  Renoprotective effect of Caralluma fimbriata against high-fat diet-induced oxidative stress in Wistar rats.

Authors:  Sudhakara Gujjala; Mallaiah Putakala; Srinivasulu Nukala; Manjunatha Bangeppagari; Rajendran Ramaswamy; Saralakumari Desireddy
Journal:  J Food Drug Anal       Date:  2016-04-13       Impact factor: 6.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.